clinical colorectal-cancer 
STAT
MARCH 13, 2024
Doctors have been eagerly waiting for data on Guardant Health’s new blood-based colorectal cancer screening test, the Shield test. The hope has been that Guardant would be able to achieve an elusive goal in colorectal cancer screening: catch incipient or early colorectal cancer using nothing more than two vials of blood.
Pharmacy Times
JUNE 12, 2023
Additionally, data from the SCARLET trial presented at ASCO 2023 indicate the safety and efficacy of sotorasib in combination with platinum-based chemotherapy treating non¬–small cell lung cancer.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JANUARY 18, 2023
The stool-test is the first-of-its-kind to detect CRC in adults aged 45 to 49 years, with a premarket approval submission planned to be sent to the FDA early in 2023.
Pharmaceutical Technology
APRIL 22, 2024
AFNT-211 is under clinical development by Affini-T Therapeutics and currently in Phase II for Colorectal Cancer.
Fierce Pharma
SEPTEMBER 22, 2023
Following a series of trial shortfalls this year in melanoma, colorectal cancer and head and neck squamous cell carcinoma, the duo has missed the mark in yet another set of clinical trials—this time in non-small cell lung cancer. . | Merck and Eisai’s Keytruda-Lenvima tag team can’t seem to catch a break.
Pharmaceutical Technology
DECEMBER 6, 2023
IGM will lay off 22% of its staff and suspend four clinical activities to advance autoimmune diseases and colorectal cancer programmes.
Pharmafile
JANUARY 5, 2023
Summary: Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, today announced that it has entered into a clinical trial collaboration and supply agreement with MSD (Merck & Co., Published date: 05/01/2023. read more.
Expert insights. Personalized for you.
127 
Let's personalize your content